lung-cancer

CALM psychotherapy helps metastatic cancer patients living in uncertain remission navigate mortality fears.

17 metastatic lung cancer and melanoma treatment responders who received CALM therapy described their experience. Four themes emerged: twilight zone between illness/health, ongoing uncertainty, struggling to adapt, and shift over time. CALM was valued for safe processing space, addressing relational strain, and whole-person acknowledgment. Mortality discussions were appreciated but felt less urgent when progression wasn't imminent.

Key Findings

Treatment responders experience 'twilight zone' with shifting identity and enduring uncertainty
CALM therapy offered safe space to process cancer and relational strain
Most participants found CALM helpful
Mortality discussions were valued but felt less urgent when progression was not imminent
CALM supports adaptation to new equilibrium as treatment responder

Implications

CALM therapy should be offered to treatment responders, not just those with limited prognosis. Oncology teams should screen for distress in patients who appear 'well.'

Caveats

Small qualitative study (n=17); single Netherlands site; abstract-only. Qualitative findings, not outcomes data.

Source: Psycho-oncology — 2026-04-01

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.